<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149342</url>
  </required_header>
  <id_info>
    <org_study_id>2013-001389-40</org_study_id>
    <nct_id>NCT02149342</nct_id>
  </id_info>
  <brief_title>Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL</brief_title>
  <official_title>Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 0.2% Hexylaminolaevulinate With 16% Methylaminolaevulinate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joint Authority for Päijät-Häme Social and Health Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Joint Authority for Päijät-Häme Social and Health Care</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study compares two photosensitizers, hexylaminolaevulinate (HAL) and
      methylaminolaevulinate (MAL), in treatment of actinic keratoses. Study is conducted using
      randomized split-face design. Efficacy is assessed clinically, and histologically at 3 and 12
      months. Pain during and after treatments and adverse reactions at one week are recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study recruites 16-20 voluuntering patients with symmetrical actinic damage on face or scalp.
      Treatment sites are randomized to receive either hexylaminolaevulinate 0.2% or
      methylaminolaevulinate ( 16% MAL) as photosensitizers (0.25mm-thick layer). A web-based
      validated program (Research Randomizer) generated a randomized list to define the treatment
      sides. The randomization results were kept blinded from the investigators who conducted the
      follow-up visits, from the pathologist, and the patients. Pre-treatment procedures include
      application of sunscreen for 15 minutes and curettage of the treatment area. Illumination is
      performed using 2 hours daylight-exposure. Efficacy is assessed clinically, and
      histologically at 3 and 12 months by blinded observers. Pain during and after treatments and
      adverse reactions at one week are recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological Lesion Clearance</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Punch biopsies were taken symmetrically on both treatment fields from equally graded &gt;6 mm AKs prior to treatment and again at 3 months, blinded observer (pathologist). HE- and p53-stainings. Samples not fulfilling the criteria of an AK were defined as healthy or completely cleared. The p53 reactivity expressed as average percentage of positive nuclei in three consecutive high power fields from the region of highest reactivity (&lt;10 % normal)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Lesion Clearance</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Clinical lesion clearance is observed by a blinded observer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Reactions</measure>
    <time_frame>One week</time_frame>
    <description>Adverse reactions are evaluated by blinded observer at one week after treatment. Severity of the reaction ( Redness, crusting and scaling) is assessed using grading: minimal, mild, intermediate, severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Assesment (Visual Analog Scale)</measure>
    <time_frame>12 hours</time_frame>
    <description>Pain using visual analog scale (VAS 0-10, where 0 is no pain and 10 is the worst pain imaginable) on both treatment sides is assessed in every 30 minutes during 2-hour sun-exposure and afterwards once in two hours until 9 p.m. (treatment day). Of these values, the mean maximal pain is assessed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clearance of Field Cancerization in Hyperspectral Images</measure>
    <time_frame>3 months</time_frame>
    <description>Data not collected</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Actinic Keratoses</condition>
  <arm_group>
    <arm_group_label>HAL cream and MAL cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hexylaminolaevulinate cream</intervention_name>
    <description>0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)</description>
    <arm_group_label>HAL cream and MAL cream</arm_group_label>
    <other_name>HAL</other_name>
    <other_name>Hexvix, Photocure</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylaminolaevulinate cream</intervention_name>
    <description>MAL 16% is used as photosensitizer for daylight-PDT</description>
    <arm_group_label>HAL cream and MAL cream</arm_group_label>
    <other_name>16% Methylaminolaevulinate (Metvix, Galderma) cream</other_name>
    <other_name>MAL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Symmetrical actinic damage on face or scalp

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Allergy to photosensitizer

          -  Photodermatose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noora E Neittaanmäki-Perttu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Päijät-Häme Cnetral Hospital, Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mari Grönroos, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Päijänne Tavastia Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Päijät-Häme Central Hospital</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <results_reference>
    <citation>Neittaanmäki-Perttu N, Grönroos M, Karppinen TT, Tani TT, Snellman E. Hexyl-5-aminolaevulinate 0·2% vs. methyl-5-aminolaevulinate 16% daylight photodynamic therapy for treatment of actinic keratoses: results of a randomized double-blinded pilot trial. Br J Dermatol. 2016 Feb;174(2):427-9. doi: 10.1111/bjd.13924. Epub 2015 Nov 20.</citation>
    <PMID>26011755</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <results_first_submitted>September 20, 2015</results_first_submitted>
  <results_first_submitted_qc>May 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 11, 2016</results_first_posted>
  <last_update_submitted>May 29, 2016</last_update_submitted>
  <last_update_submitted_qc>May 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Actinic keratoses</keyword>
  <keyword>Daylight-PDT</keyword>
  <keyword>Hexylaminolaevulinate</keyword>
  <keyword>HAL</keyword>
  <keyword>Methylaminolaevulinate</keyword>
  <keyword>MAL</keyword>
  <keyword>Hyperspectral imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyl 5-aminolevulinate</mesh_term>
    <mesh_term>Aminolevulinic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>International peer-reviewed publication</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hexylaminolaevulinate and Methylaminoalevulinate Creams</title>
          <description>0,2% hexylaminolaevulinate cream , HAL (Hexvix, Photocure, Unguentum M, Almirall) 16% methylaminolaevulinate, MAL (Metvix, Galderma)
HAL and MAL used as photosensitizer for daylight-PDT in a randomized split-face design</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14">14 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">14 patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hexylaminolaevulinate and Methylaminoalevulinate Cream</title>
          <description>0.2% hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and 16% methylaminolaevulinate (Metvix, Galderma) in a split-face design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" lower_limit="66" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Histological Lesion Clearance</title>
        <description>Punch biopsies were taken symmetrically on both treatment fields from equally graded &gt;6 mm AKs prior to treatment and again at 3 months, blinded observer (pathologist). HE- and p53-stainings. Samples not fulfilling the criteria of an AK were defined as healthy or completely cleared. The p53 reactivity expressed as average percentage of positive nuclei in three consecutive high power fields from the region of highest reactivity (&lt;10 % normal)</description>
        <time_frame>Baseline, 3 months</time_frame>
        <population>One patient was excluded from the histological analysis because one biopsied lesion clinically taken as an AK appeared histologically to be seborrheic eczema.</population>
        <group_list>
          <group group_id="O1">
            <title>Hexylaminolaevulinate Cream</title>
            <description>0.2% hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral)
Hexylaminolaevulinate cream: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream</description>
          </group>
          <group group_id="O2">
            <title>Methylaminolaevulinate Cream</title>
            <description>16% methylaminolaevulinate (Metvix, Galderma)
Methylaminolaevulinate cream: MAL 16% is used as photosensitizer for daylight-PDT</description>
          </group>
        </group_list>
        <measure>
          <title>Histological Lesion Clearance</title>
          <description>Punch biopsies were taken symmetrically on both treatment fields from equally graded &gt;6 mm AKs prior to treatment and again at 3 months, blinded observer (pathologist). HE- and p53-stainings. Samples not fulfilling the criteria of an AK were defined as healthy or completely cleared. The p53 reactivity expressed as average percentage of positive nuclei in three consecutive high power fields from the region of highest reactivity (&lt;10 % normal)</description>
          <population>One patient was excluded from the histological analysis because one biopsied lesion clinically taken as an AK appeared histologically to be seborrheic eczema.</population>
          <units>percentage of complete histological clea</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Punch biopsies</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="0" upper_limit="100"/>
                    <measurement group_id="O2" value="69.2" lower_limit="0" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Lesion Clearance</title>
        <description>Clinical lesion clearance is observed by a blinded observer</description>
        <time_frame>Baseline, 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hexylaminolaevulinate Cream</title>
            <description>0.2% hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) (2014) 2% hexylaminolaevulinate (Hexvix Photocure) mixed with Unguentum M (Allmiral) (2015)
Hexylaminolaevulinate cream: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)</description>
          </group>
          <group group_id="O2">
            <title>Methylaminolaevulinate Cream</title>
            <description>16% methylaminolaevulinate (Metvix, Galderma)
Methylaminolaevulinate cream: MAL 16% is used as photosensitizer for daylight-PDT</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Lesion Clearance</title>
          <description>Clinical lesion clearance is observed by a blinded observer</description>
          <units>percentage of lesions in complete respon</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>AK lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" lower_limit="28.6" upper_limit="100"/>
                    <measurement group_id="O2" value="77.8" lower_limit="44.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Reactions</title>
        <description>Adverse reactions are evaluated by blinded observer at one week after treatment. Severity of the reaction ( Redness, crusting and scaling) is assessed using grading: minimal, mild, intermediate, severe.</description>
        <time_frame>One week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hexylaminolaevulinate Cream</title>
            <description>0.2% hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) (2014) 2% hexylaminolaevulinate (Hexvix Photocure) mixed with Unguentum M (Allmiral) (2015)
Hexylaminolaevulinate cream: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)</description>
          </group>
          <group group_id="O2">
            <title>Methylaminolaevulinate Cream</title>
            <description>16% methylaminolaevulinate (Metvix, Galderma)
Methylaminolaevulinate cream: MAL 16% is used as photosensitizer for daylight-PDT</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Reactions</title>
          <description>Adverse reactions are evaluated by blinded observer at one week after treatment. Severity of the reaction ( Redness, crusting and scaling) is assessed using grading: minimal, mild, intermediate, severe.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Assesment (Visual Analog Scale)</title>
        <description>Pain using visual analog scale (VAS 0-10, where 0 is no pain and 10 is the worst pain imaginable) on both treatment sides is assessed in every 30 minutes during 2-hour sun-exposure and afterwards once in two hours until 9 p.m. (treatment day). Of these values, the mean maximal pain is assessed.</description>
        <time_frame>12 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hexylaminolaevulinate Cream</title>
            <description>0.2% hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) (2014) 2% hexylaminolaevulinate (Hexvix Photocure) mixed with Unguentum M (Allmiral) (2015)
Hexylaminolaevulinate cream: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)</description>
          </group>
          <group group_id="O2">
            <title>Methylaminolaevulinate Cream</title>
            <description>16% methylaminolaevulinate (Metvix, Galderma)
Methylaminolaevulinate cream: MAL 16% is used as photosensitizer for daylight-PDT</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Assesment (Visual Analog Scale)</title>
          <description>Pain using visual analog scale (VAS 0-10, where 0 is no pain and 10 is the worst pain imaginable) on both treatment sides is assessed in every 30 minutes during 2-hour sun-exposure and afterwards once in two hours until 9 p.m. (treatment day). Of these values, the mean maximal pain is assessed.</description>
          <units>Mean maximal pain VAS score</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.1" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1" lower_limit="0.1" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clearance of Field Cancerization in Hyperspectral Images</title>
        <description>Data not collected</description>
        <time_frame>3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse reactions were assessed by blinded observer at one week after treatment Cosmetic outcome was evaluated at 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hexylaminolaevulinate Cream</title>
          <description>0.2% hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) (2014) 2% hexylaminolaevulinate (Hexvix Photocure) mixed with Unguentum M (Allmiral) (2015)
Hexylaminolaevulinate cream: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)</description>
        </group>
        <group group_id="E2">
          <title>Methylaminolaevulinate Cream</title>
          <description>16% methylaminolaevulinate (Metvix, Galderma)
Methylaminolaevulinate cream: MAL 16% is used as photosensitizer for daylight-PDT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Redness, crusting, scaling; minimal</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Redness, scaling, crusting; Mild</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Redness, crusting, scaling; intermediate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Redness, scaling, crusting; Severe</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As the study was conducted as a single center pilot study, the results should be confirmed in a larger trial also valuing the patient complete response rates. A further limitation was we did not record light-doses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Md, PhD Noora Neittaanmäki-Perttu</name_or_title>
      <organization>Helsinki university central hospital</organization>
      <phone>+358407190362</phone>
      <email>noora.neittaanmaki@fimnet.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

